menu search

THTX / Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
MONTREAL, March 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new data will be presented demonstrating the promise of its SORT1+ Technology™ platform of proprietary peptides, and of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in enabling targeted delivery of anticancer therapy. Read More
Posted: Mar 14 2023, 18:42
Author Name: GlobeNewsWire
Views: 112545

THTX News  

Why Is Theratechnologies (THTX) Stock Down 22% Today?

By InvestorPlace
October 26, 2023

Why Is Theratechnologies (THTX) Stock Down 22% Today?

Theratechnologies (NASDAQ: THTX ) stock is dropping on Thursday after the biopharmaceutical company announced a proposed public share offering. Thera more_horizontal

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

By GlobeNewsWire
September 7, 2023

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biophar more_horizontal

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

By GlobeNewsWire
May 25, 2023

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharma more_horizontal

Theratechnologies stock price continues higher on company guidance

By Proactive Investors
April 14, 2023

Theratechnologies stock price continues higher on company guidance

Theratechnologies (TSX:TH) Inc shares continued to advance Friday, up 12% to $1.29 following a 10% gain on Thursday, after the biopharmaceutical compa more_horizontal

Theratechnologies Inc. (THTX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
April 12, 2023

Theratechnologies Inc. (THTX) Q1 2023 Earnings Call Transcript

Theratechnologies Inc. (NASDAQ:THTX ) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor more_horizontal

Theratechnologies shares up as first quarter revenues rise

By Proactive Investors
April 12, 2023

Theratechnologies shares up as first quarter revenues rise

Theratechnologies (TSX:TH) has reported first-quarter financial results with consolidated revenue growing by 7% to US$19.9mln. The Montreal-headquarte more_horizontal

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

By GlobeNewsWire
March 14, 2023

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

MONTREAL, March 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biophar more_horizontal

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

By GlobeNewsWire
February 14, 2023

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company foc more_horizontal


Search within

Pages Search Results: